HC Wainwright reiterated their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) in a research report released on Wednesday, Benzinga reports. HC Wainwright currently has a $75.00 price target on the stock.
Aligos Therapeutics Trading Down 7.0 %
ALGS stock opened at $8.40 on Wednesday. The company’s 50 day moving average is $10.59 and its 200 day moving average is $13.44. The stock has a market cap of $656.12 million, a price-to-earnings ratio of -6.56 and a beta of 2.16. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $30.00.
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.00) by $4.75. The company had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same quarter last year, the firm posted ($10.75) earnings per share. As a group, sell-side analysts forecast that Aligos Therapeutics will post -8.2 EPS for the current fiscal year.
Institutional Investors Weigh In On Aligos Therapeutics
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Featured Articles
- Five stocks we like better than Aligos Therapeutics
- The 3 Best Fintech Stocks to Buy Now
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Use the MarketBeat Dividend Calculator
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.